Table 3.
Hypertension and hyperlipidaemia medication usage among patients, stratified by body mass index (BMI) category
| Variable | Total | BMI (kg/m2) | ||||
| N (%) | <25 | 25–29.9 | 30–34.9 | 35–39.9 | ≥40 | |
| All subjects | 324 199 (100.0%) | 68 424 (21.1%) | 121 287 (37.4%) | 75 199 (23.2%) | 34 152 (10.5%) | 25 137 (7.8%) |
| Hypertension medication | 120 993 (37.3%) | 13 345 (19.5%) | 43 014 (35.5%) | 33 774 (44.9%) | 17 219 (50.4%) | 13 641 (54.3%) |
| Number of classes of hypertension medications, median (IQR) | 0 (0–2) | 0 (0–0) | 0 (0–2) | 0 (0–2) | 1 (0–2) | 1 (0–2) |
| Cholesterol-lowering medications | 83 637 (25.8%) | 8288 (12.1%) | 33 802 (27.9%) | 23 982 (31.9%) | 10 626 (31.1%) | 6939 (27.6%) |
| Statin+second drug (non-statin)* |
8915 (2.7%) | 646 (0.9%) | 3586 (3.0%) | 2698 (3.6%) | 1264 (3.7%) | 721 (2.9%) |
| Statin only | 69 071 (21.3%) | 6921 (10.1%) | 28 068 (23.1%) | 19 696 (26.2%) | 8657 (25.3%) | 5729 (22.8%) |
| Non-statin drug only | 5651 (1.7%) | 721 (1.1%) | 2148 (1.9%) | 1588 (1.8%) | 705 (2.1%) | 489 (2.1%) |
All measured associations between the weight classifications and the patient characteristics were statistically significant with a P value<0.0001.
*Non-statin cholesterol-lowering medications included bile acid sequestrants, fibrates and other dyslipidemia drugs that comprise a variety of different mechanisms of action.